rilzabrutinib

China [CN]

Rilzabrutinib, also known as research code PRN1008 and SAR-444671, carries CAS registry number 1575596-29-0 with molecular formula C₃₆H₄₀FN₉O₃ and molecular weight of 665.77. Its full stereochemical systematic name is (αE,3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-α-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-β-oxo-1-piperidinepropanenitrile. This chiral compound is a white to off-white solid, with a predicted boiling point of 882.5±65.0 °C and a predicted density of 1.39±0.1 g/cm³. It achieves high solubility in DMSO at up to 120.0 mg/mL (180.24 mM), which supports cellular pharmacological testing. Long-term storage at -20 °C is required to maintain stability; its full structural identifiers including InChIKey and SMILES string are provided for synthetic, chromatographic and analytical laboratory reference. Functionally, Rilzabrutinib acts as a reversible, selective, orally bioavailable covalent Bruton’s Tyrosine Kinase (BTK) inhibitor with an IC50 value of 1.3 nM. It is widely utilized as a core research reagent for preclinical investigations of B-cell signaling, autoimmune disorders and hematological malignancies, and is available as solid powder as well as pre-formulated 10 mM DMSO stock solution for in vitro biochemical and cellular mechanism studies.